ACCELERON PHARMA INC. (NASDAQ:XLRN) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD Disclosure.
ACCELERON PHARMA INC. (NASDAQ:XLRN) Files An 8-K Regulation FD Disclosure
On January 6, 2017, Acceleron Pharma Inc., or Acceleron, issued a press release outlining its corporate goals and priorities for 2017. On January 9, 2017, Acceleron uploaded a slide presentation to its website discussing the current state of the company and outlining its corporate goals and priorities for 2017. Copies of the press release and the slide presentation are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively.
The furnishing of the attached press release and slide presentation is not an admission as to the materiality of any information therein. The information contained in the press release and slides is summary information that is intended to be considered in the context of more complete information included in Acceleron’s filings with the Securities and Exchange Commission and other public announcements that Acceleron has made and may make from time to time by press release or otherwise. Acceleron undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate.
The information contained in this Item, including Exhibit 99.1 and Exhibit 99.2 attached hereto, is being furnished and shall not be deemed “filed” for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
99.1 Press Release of Acceleron Pharma Inc. dated January 6, 2017.
99.2 Slide presentation of Acceleron Pharma Inc. dated January 9, 2017.
About ACCELERON PHARMA INC. (NASDAQ:XLRN)
Acceleron Pharma Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutic candidates that are based on mechanisms, which the human body uses to regulate the growth and repair of its cells and tissues. Its therapeutic candidates are used to treat serious and rare diseases. The Company’s pipeline includes Luspatercept, Sotatercept, Dalantercept, ACE-083, ACE-2494, ACE-1332, ACE-3891, ACE-2798, ACE-2536 and ACE-2395. Luspatercept promotes red blood cell production. It is developing Sotatercept for the treatment of chronic kidney disease. Dalantercept treats cancers by inhibiting blood vessel formation by inhibiting signaling through the activin receptor-like kinase (ALK) 1 receptor. ACE-083 is for the treatment of focal muscle disorders. ACE-2494 is designed to treat systemic muscle disorders. ACE-3891, ACE-1332, ACE-2798, ACE-2536 and ACE-2395 are in preclinical stage of development. ACCELERON PHARMA INC. (NASDAQ:XLRN) Recent Trading Information
ACCELERON PHARMA INC. (NASDAQ:XLRN) closed its last trading session up +0.27 at 26.52 with 499,385 shares trading hands.
Acceleron Pharma Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutic candidates that are based on mechanisms, which the human body uses to regulate the growth and repair of its cells and tissues. Its therapeutic candidates are used to treat serious and rare diseases. The Company’s pipeline includes Luspatercept, Sotatercept, Dalantercept, ACE-083, ACE-2494, ACE-1332, ACE-3891, ACE-2798, ACE-2536 and ACE-2395. Luspatercept promotes red blood cell production. It is developing Sotatercept for the treatment of chronic kidney disease. Dalantercept treats cancers by inhibiting blood vessel formation by inhibiting signaling through the activin receptor-like kinase (ALK) 1 receptor. ACE-083 is for the treatment of focal muscle disorders. ACE-2494 is designed to treat systemic muscle disorders. ACE-3891, ACE-1332, ACE-2798, ACE-2536 and ACE-2395 are in preclinical stage of development. ACCELERON PHARMA INC. (NASDAQ:XLRN) Recent Trading Information
ACCELERON PHARMA INC. (NASDAQ:XLRN) closed its last trading session up +0.27 at 26.52 with 499,385 shares trading hands.
